文献速递泌尿生殖MR

前列腺癌诊断中磁共振孔径内靶向活检的组织病理学检出率与一致性

Histopathologic Yields and Concordance of In-Bore MRI-targeted Biopsy for Prostate Cancer Diagnosis.
PubMed 文献 · Radiology · 2025-01-01

这项回顾性研究评估了2015年3月至2023年1月间进行的磁共振孔径内靶向活检,共纳入780个病灶。结果显示,PI-RADS≥4类和病灶>10 mm的患者中GG≥2级前列腺癌检出率更高;活检GG 1级病灶的手术升级风险较高(66.1% vs 16.0%)。在216例根治性前列腺切除术患者中,活检与手术分级一致性中等至较好(加权κ=0.61)。

要点

  • PI-RADS≥4类且病灶>10 mm者GG≥2级前列腺癌检出率更高。
  • 活检GG 1级病灶手术升级率66.1%,显著高于GG 2-4级的16.0%。
  • 活检与手术分级一致性中等至较好,加权κ=0.61(95%CI:0.51,0.71)。

核心结论

  • 磁共振孔径内靶向活检对GG≥2级前列腺癌的检出率取决于靶病灶大小和PI-RADS分类,活检GG 1级病灶存在较高的组织学升级风险。

研究设计与样本

  • 回顾性研究,评估2015年3月至2023年1月间进行的磁共振孔径内靶向活检,共纳入780个病灶(患者中位年龄65岁,IQR 59-70岁);采用Cohen加权κ评估活检分级(bGG)与手术分级(sGG)的一致性。

诊断标准与关键数值

  • 在既往活检阴性和初次活检患者中,PI-RADS≥4类病灶的GG≥2级癌检出率分别为42.5%和46.5%,病灶>10 mm者分别为45.1%和43.4%(P<.05);216例根治性前列腺切除术患者中bGG与sGG加权κ=0.61(95%CI:0.51,0.71);bGG与sGG相差≥2级降级罕见(5.7%);组织病理学一致性不依赖于PI-RADS分类、靶病灶大小、活检系统或患者活检状态(P=.90)。

临床应用与阅片要点

  • 磁共振孔径内靶向活检对GG≥2级前列腺癌的检出率与靶病灶大小和PI-RADS分类相关,活检GG 1级病灶存在较高的组织学升级风险。

局限性

  • 原文指出,影响前列腺癌检出率的因素以及分级和患者风险迁移的可能性需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background MRI-targeted biopsies are recommended for prostate cancer diagnosis. In-bore MRI-targeted biopsy enables high-precision needle placement; however, the factors affecting prostate cancer detection rates and the potential for grade and patient risk migration require further investigation. Purpose To evaluate factors affecting the detection rate of prostate cancer in patients who underwent in-bore MRI-targeted biopsy and their influence on histologic concordance between biopsy (bGG) and surgical grade group (sGG). Materials and Methods This retrospective study evaluated in-bore MRI-targeted biopsies performed between March 2015 and January 2023. The agreement between bGG and sGG was assessed using Cohen weighted κ. The detection rate of prostate cancer and the concordance rates between bGG and sGG in patients undergoing prostatectomy were compared between biopsy systems (manual and robotic) and by patient biopsy status, lesion size (≤10 mm vs >10 mm), and Prostate Imaging Reporting and Data System (PI-RADS) category. Results In total, 780 lesions (patient median age, 65 years [IQR, 59-70 years]) were included. Among patients with previous negative biopsy and biopsy-naive patients, the detection rates of grade group (GG) 2 or higher cancer were higher in patients with PI-RADS category 4 or higher lesions (42.5% and 46.5%) and lesions larger than 10 mm (45.1% and 43.4%) (P < .05). Surgical upgrading was higher in lesions with bGG 1 than in those with bGG 2-4 cancers (66.1% vs 16.0% [P < .001]). In the 216 patients undergoing radical prostatectomy, bGG and sGG showed moderate to substantial agreement (weighted κ correlation coefficient, 0.61 [95% CI: 0.51, 0.71]). A downgrade of two or more grades between bGG and sGG was rare (5.7%). Histopathologic concordance did not depend on the PI-RADS category, target lesion size, biopsy system, or patient biopsy status (P = .90). Conclusion The in-bore MRI-targeted biopsy detection rates for GG 2 or higher prostate cancer depend on the target lesion size and PI-RADS category, and there is a substantial risk of histologic upgrades in men with GG 1 lesions at MRI-targeted biopsy. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Milot in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sattin C, Pizzi C, Summers P, et al. Histopathologic Yields and Concordance of In-Bore MRI-targeted Biopsy for Prostate Cancer Diagnosis. Radiology. 2025. PMID: 40728405. doi:10.1148/radiol.241710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。